Relapsed or relapsed/refractory multiple myeloma (MM) with progressive disease (PD) parameters according to International Myeloma Working Group (IMWG) criteria\r\n* Refractory is defined as experiencing less than minimal response to or PD within  days of the most recent line therapy\r\n* Relapsed is defined as patients requiring salvage therapy for PD who are not refractory to the most recent line of therapy
Refractory to or relapsed after at least  prior treatment line.
Have high-risk relapsed or refractory Hodgkin lymphoma (HL), defined as at least one of the following:\r\n* Primary refractory disease to front-line therapy\r\n* Relapse within  year of completing front-line therapy\r\n* Extranodal involvement at the time of pre-ASCT relapse\r\n* B symptoms at pre-ASCT relapse\r\n* More than one type of pre-ASCT salvage therapy required
Must have relapsed or refractory disease after  or more prior lines of therapy;  line of therapy is allowed, if it included an autologous stem cell transplant and at least  weeks have elapsed from day ; a line of therapy is defined as a course of therapy that is not interrupted by progressive disease
TREATMENT INCLUSION: Diagnosis and clinical course falling into one of the following categories:\r\n* Hodgkin lymphoma refractory to second line chemotherapy; relapsed or progressive after high dose therapy/autologous stem cell transplantation; relapsed or progressive after treatment with brentuximab or a checkpoint inhibitor\r\n* Aggressive non-Hodgkin lymphoma refractory to second line chemotherapy; relapsed or progressive after high dose therapy/autologous stem cell transplantation\r\n* ALK-negative anaplastic T cell lymphoma or other peripheral T-cell lymphoma refractory to first line chemotherapy; relapsed after first line therapy (possibly including high dose therapy/autologous stem cell transplantation)\r\n* ALK-positive anaplastic T cell lymphoma refractory to second line therapy; relapsed after second line therapy
Biopsy-proven, measurable, stage IB-IVB relapsed or refractory cutaneous T-cell lymphoma after  lines of skin-directed therapy or one prior line of systemic therapy (Note: extracorporeal photopheresis will be considered a systemic therapy for this study)
Patients must be either refractory to or relapsed after  line of therapy
Biopsy-proven, measurable, stage IB-IVB relapsed or refractory cutaneous T-cell lymphoma after  lines of skin-directed therapy or one prior line of systemic therapy\r\n* Note: extracorporeal photopheresis will be considered a systemic therapy for this study
Must have biopsy-proven primary refractory disease or relapsed disease after front-line chemo-immunotherapy (with anti-CD monoclonal antibody [mAb]) in combination with anthracycline-based chemotherapy) or at least one of the following\r\n* For subjects with DLBCL: relapsed or refractory disease after ?  prior line(s) of therapy; for both de novo and transformed disease, patients must have received at least  prior regimen with anti-CD mAb and anthracycline\r\n* For subjects with FL or SLL: relapsed or refractory disease after ?  prior line(s) of therapy\r\n* For subjects with CLL: must be relapsed or refractory disease and\r\n** with no unfavorable cytogenetics and have failed ?  prior line(s) of therapy\r\n** with unfavorable cytogenetics including delp/mutated p or unmutated immunoglobulin heavy chain variable region relapsed or refractory disease after ?  prior line(s) of therapy which must have included ibrutinib\r\n* For subjects with MCL: relapsed or refractory disease after at least  prior regimen with chemoimmunotherapy\r\n* For subjects with Burkitts: relapsed or refractory disease after at least  prior line of therapy\r\n* Any patient, with subtypes listed above, having either failed autologous HSCT after at least  prior regimen, or those patients ineligible for, but not an appropriate candidate, or not consenting to autologous HSCT
Have relapsed, refractory, or progressive disease following last line of treatment
Relapsed or refractory disease after first-line chemoimmunotherapy
Patient must be either refractory to or relapsed after  line of therapy; prior radiation therapy is allowed
Patients must be either refractory to or relapsed after  line of therapy; exception: in the expansion cohort only, no BV refractory patients will be allowed
Primary refractory (at least  prior line of therapy)
At least  prior line of therapy if primary refractory or relapsed within  year. Subjects who respond to initial therapy for greater than or equal to  year must have had at least  prior lines of therapy including an anti-CD monoclonal antibody.
PHASES  AND : patient participants with AML that has relapsed after, or is refractory to, first-line therapy, with or without subsequent additional therapy, and are currently considered unfit for, or unlikely to respond to, cytotoxic chemotherapy
At least  prior line of chemoimmunotherapy if primary refractory or relapsed within one year; subjects who respond to initial therapy for greater than one year must have had at least  prior lines of therapy including one line with chemoimmunotherapy including an anti-CD monoclonal antibody
Patients must be either refractory to or relapsed after  line of therapy
Patient must be either refractory to or relapsed after  line of therapy
Have relapsed or refractory MM after at least one line of therapy
Disease which has relapsed, or is refractory, following at least one line of therapy, with no therapy of higher priority available.
Recurrence or refractory to  line of systemic chemotherapy.
Subjects must be primary refractory or relapsed to st line intensive treatment for AML or refractory or relapsed after second line of treatment for AML
AML has relapsed after, or is refractory to, first-line therapy, with or without additional subsequent therapy
Relapsed or refractory after at least  front-line therapy
Refractory to first-line AML therapy is defined as:
Part B: Diagnosis of MM with relapsed or refractory disease with previous exposure to PI (e.g., bortezomib or carfilzomib), IMiDs (e.g., lenalidomide or pomalidomide), and daratumumab, and refractory (based on IMWG criteria) to their last line of therapy
Has evidence of persistent or recurrent AML in the peripheral blood and/or bone marrow that is refractory to, or has relapsed from, their most recent prior line of treatment.
Has evidence of persistent or recurrent AML in the peripheral blood and/or bone marrow that is refractory to, or has relapsed from, their most recent prior line of treatment.
Refractory to or relapsed after at least  prior treatment line.
Patients must have progressed on or within  days after end of previous therapy before to study entry, i.e., refractory to the last line of treatment.
have MCL that relapsed after or is refractory to (a) first-line combination chemotherapy with or without stem cell transplant and (b) at least  other locally available therapy
For arms A and B, participants must have relapsed after or been refractory to first-line chemotherapy, i.e., they must have failed to achieve CR after first-line therapy or must have relapsed subsequently if they achieved CR; for arm C, participants will be eligible if transplant is performed as consolidation of first remission (partial or complete)
Histologically or cytologically proven SCLC that has relapsed or been refractory after at least one line of chemotherapy
Relapsed or refractory CLL or SLL following at least  prior line of systemic therapy consisting of at least  cycles of a chemotherapy-containing regimen
Was refractory to lenalidomide or proteasome inhibitor-based therapy at any line. NOTE: Refractory disease was defined as disease progression on treatment or progression within  days after the last dose of a given therapy. Participants who progressed after  days from the last dose of a given therapy were considered relapsed and were eligible for inclusion in the study. Participants who were refractory to thalidomide-based therapy were eligible.
Must have relapsed or refractory disease (refractory is defined as progression during treatment or within  days after the completion of treatment) requiring nd or rd line therapy
Relapsed or relapse/refractory MM with at least  prior line of therapy for phase  and  to  prior lines of therapy for phase .
Relapsed or refractory disease after at least one line of prior therapy. Subjects must have previously received appropriate line(s) of standard of care (SOC) treatment.
Untreated relapse of cHL (with the exception of steroids) as follows:\r\n* HL that relapsed >=  months after completion of first-line chemotherapy or combined modality therapy, and has not yet been treated with salvage chemotherapy\r\n* Stage I-II HL that relapsed >=  months after first-line chemotherapy, then relapsed after radiation therapy delivered with curative intent, and has not yet been treated with salvage chemotherapy
Progressed or refractory to at least  prior line of standard therapy
Patients must have relapsed or refractory disease after ? prior line of treatment.
Documentation of at least one line of prior myeloma therapy now with relapsed or refractory disease requiring re-treatment
Patients with relapsed or refractory systemic ALCL who have previously received front line chemotherapy.
Patients must have received at least one prior line of therapy and their disease has relapsed..
Participants who are refractory or relapsed after at least  prior line of therapy and for whom no effective standard therapy is available per the investigator's assessment.
Relapsed after or are refractory to at least one prior line of chemotherapy which have not included a taxane (with the exception of Cohort  of the Lead-In Phase which will allow the enrollment of subjects with prior treatment with a taxane)
Patients are relapsed from or refractory to at least  previous line of therapy
Patients must have relapsed/refractory disease, with at least one line of prior chemotherapy, but =<  prior lines of treatment, for Hodgkin lymphoma; NOTE: patients must not have had prior immune checkpoint inhibitors; however, there are no other limitations to prior agent or regimen types
Refractory or relapsed after at least  prior line of therapy for whom no effective standard therapy is available per investigator's assessment.  Participants who are either treatment-naive to, relapsed after, or refractory to ibrutinib, idelalisib, or any other investigational B cell receptor (BCR) pathway inhibitors not directly targeting spleen tyrosine kinase (SYK) are allowed.
